Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Naloxone Efficacy Standard Changes Could Impact Amphastar's Pending NDA

Oct 12 2016

• By Sue Sutter

Related Content

Higher Naloxone Doses Narrowly Favored By FDA Panel

Oct 06 2016

FDA’s Naloxone Product Approval Standards May See Changes

Oct 04 2016

Related Companies

Amphastar Pharmaceuticals, Inc.

Kaléo Pharmaceutical Inc.

Adapt Pharma Limited

Endo, Inc.

INSYS Therapeutics, Inc.

Additional Topics

Regulation Advisory Committees Drug Approval Standards BioPharmaceutical

More from US FDA Performance Tracker

More from Regulatory Trackers

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window